Richmond Pharmacology take part in the MS Society Wheel and Walk: A great Success for all!

Posted:
15
July 2008

MHRA

MHRA

Richmond Pharmacology, the 1st Early Phase CRO to receive MHRA Standard and Supplementary Accreditation for 2 hospital based Clinical Trial Centers.Richmond Pharmacology. (RPL) have proudly received MHRA Standard and Supplementary Accreditation, a clear sign of our continued commitment to providing the highest level of subject safety on all studies conducted within our two hospital based Early Phase trial centres. RPL is unique in being the only Early Phase CRO in the UK to have two trial centres based in two acute NHS teaching hospitals.The supplementary accreditation confirms that RPL have attained the highest level of accreditation available in Europe. This permits RPL to perform the full range of Early Phase studies, including trials requiring a review of risk factors by the Expert Advisory Group (EAG).The combination of this accreditation award, our experience from conducting in excess of 400 Early Phase studies and our world-leading scientific advisory board means our sponsors can rely on RPL to continue to lead the industry in the conduct of FTIM studies, as well as other specialty areas such as TQT Studies, Japanese bridging studies, gastrointestinal studies and patient studies.For more information on the MHRA Phase I accreditation scheme visit the MHRA website.For further information on RPL's Early Phase facilities and expertise,please review our brochures.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more